In addition to the previously discussed case report in which the tumor of the cholangiocarcinoma patient harbored a neoantigen ERBB2IP E805G, Rosenberg reported several cases treated in a similar manner, including a patient with metastatic colorectal cancer infused with KRAS-G12D targeted TILs and a chemorefractory HR-positive patient with metastatic breast cancer treated with TILs against four mutations distributed in SLC3A2, KIAA0368, CADPS2, and CTSB, respectively. Here, ERBIN is linked to neoplasm.